IPO: MGC Pharma

The first medicinal cannabis company lists in London

In February 2021 Tavistock helped make history as PR advisor to MGC Pharmaceuticals, the first medicinal cannabis company to IPO on the London Stock Exchange, which raised £6.5m in the process.

MGC Pharma is a European based bio-pharma company developing and supplying affordable standardised phyto-medicines to patients globally. It’s research and treatments are focused on using phytomedicines in three core areas: Neurology, Oncology, and Autoimmune diseases – including ArtemiC™ for treatment of Covid-19 infected patients.

Other Case Studies

Financial and Corporate PR: Vodafone Group plc

READ MORE

Financial PR: Avast plc

With 435 million users, Avast plc is one of the largest global cybersecurity companies. Tavistock was appointed by Avast in 2018 following its £2.4bn IPO on the LSE in 2018.

READ MORE

Corporate Campaign: Rolls Royce

Tavistock was hired by Rolls Royce to assist on its communications for its Small Modular Reactor technology (SMR). The brief was put out to competitive tender to design a campaign for SMRs to respond to a £250m UK Government research grant programme.

READ MORE

M&A: Dee Valley

Tavistock advised the Board of Dee Valley Water on Severn Trent's £84 million takeover bid.

READ MORE

M&A: Gemfields

Tavistock advised the Board of Gemfields plc during its £220m hostile takeover.

READ MORE

IPO: Ten Lifestyle

Tavistock advised Ten Lifestyle Group plc on its IPO onto the AIM Market of the London Stock Exchange.

READ MORE

Dual Listing: Resolute Mining

Tavistock advised Resolute on its 2019 dual listing on the London Stock Exchange.

READ MORE